The article examines the objective, findings, and clinical context described in FDA approves giredestrant for breast cancer.
Approach:
Approval: The FDA approved giredestrant (Wilserdly) with everolimus for adults whose disease recurred during or after endocrine-based adjuvant therapy or progressed on at least one endocrine-based regimen in the metastatic setting. FoundationOne Liquid CDx was authorize…
Trial: Approval was supported by the phase 3, randomized, open-label evERA Breast Cancer trial. It enrolled 373 adults; 207 had ESR1-mutated tumors. Participants received giredestrant 30 mg once daily or physician-selected exemestane, fulvestrant, or tamoxifen, with …
Key Findings:
In patients with ESR1-mutated tumors, median investigator-assessed progression-free survival was 10 months with giredestrant plus everolimus versus 5.5 months with comparator endocrine therapy plus everolimus; the difference was statistically significant.
Objective response rates were 27% and 14%, respectively.
Overall survival data were immature at the time of the progression-free survival analysis.
Common adverse reactions occurring in at least 20% of patients receiving the combination included stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea.
Bradycardia occurred in 3.8% of combination-treated patients in the trial; all cases were asymptomatic. The prescribing information also warns of embryo-fetal toxicity.
Interpretation:
The FDA approval is for the specified ESR1-mutated population and is supported by longer progression-free survival with giredestrant plus everolimus than with the comparator combination in evERA.
Limitations:
Overall survival data were immature at the time of the progression-free survival analysis.
Conclusion:
The recommended giredestrant dose is 30 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. The prescribing information advises avoiding strong CYP3A inhibitors and inducers and recommends more frequent heart-rate monitoring for patients with preexisting bradycardia or taking heart-rate-slowing medications.
A JAMA Internal Medicine Viewpoint urges clinicians and health systems to verify risk-model inputs before acting on automated breast cancer screening recommendations.